The development of the novel Alzheimer’s disease treatment options is among the most vital health needs across the world today. In a bid to develop therapeutic vaccine for this disease , Sweden-based Alzinova AB has reportedly announced plans to advance its vaccine candidate named ‘ALZ-101’ at the CTAD (Clinical Trials on Alzheimer's disease digital meet.

For the record, Alzinova AB is a Swedish biopharma firm focusing on the development of novel treatment options for Alzheimer's disease by aiming neurotoxic amyloid-β oligomers. The lead vaccine candidate, ALZ-101, is a unique therapeutic vaccine against the oligomeric, neurotoxic form of Aβ 1-42 and is presently in the preclinical development stage.

Alzinova AB said in a meeting that the company will conduct a Phase I study in patients with initial stage Alzheimer’s disease and is anticipated to commence during Q2 2020. This is a first-in-human clinical study, and the main objective is to evaluate the tolerability and unexpected adverse events of the ALZ-101 vaccine candidate.

The clinical will further include an evaluation of the immune response that is levels of antibodies created by the vaccine after constant dosing. The study will be commenced in Finland in collaboration with Clinical Research Services Turku - CRST Oy.

Speaking on which, Kristina Torfgård, CEO of Alzinova AB said that based on the documented pre-clinical outcomes, the company is looking forward to the development of ALZ-101 into a therapeutic vaccine for patients.

It is first of kind clinical trial that particularly targets the toxic forms of the Aβ peptide Mr. Torfgård said while adding that this is an important step in a field where the medical need is great.

The arrangements to submit the application and commence the study will continue according to plan. The main aim is to start the study during Q2 2021.

Source credit - https://www.prnewswire.com/news-releases/alzinova-ab-announces-the-study-design-for-the-first-clinical-study-with-the-oligomer-specific-therapeutic-vaccine-alz-101-at-a-scientific-congress-301166302.html